Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
COGT
Stock Latest News
The Fly
Cogent Biosciences announces preclinical data from KRAS, ErbB2 programs
1d ago
COGT
Premium
Ratings
Bezuclastinib’s Strong Phase 3 GIST Data and NDA Catalyst Support Buy Rating and $52 Target
16d ago
COGT
Premium
The Fly
Cogent Biosciences submits bezuclastinib new drug application to the FDA
17d ago
COGT
Premium
Company Announcements
Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers
22d ago
COGT
Premium
The Fly
Cogent Biosciences assumed with a Buy at Jefferies
1M ago
COGT
Premium
The Fly
Cogent Biosciences: FDA accepts NDA for bzuclastinib in NonAdvSM
1M ago
COGT
Premium
The Fly
Cogent announces additional results from SUMMIT trial of bezuclastinib
2M ago
COGT
Premium
The Fly
Cogent Biosciences price target raised to $35 from $34 at Baird
2M ago
COGT
Premium
Ratings
Buy Rating Backed by Bezuclastinib’s Late-Stage Catalysts, Dual-Launch Potential, and Differentiated Profile in GIST and SM
2M ago
COGT
Premium
The Fly
Cogent Biosciences price target raised to $52 from $39 at Piper Sandler
2M ago
COGT
Premium
Company Announcements
Analyst Warns Bezuclastinib’s FDA Breakthrough and RTOR Status May Not Translate Into Faster Approvals or Investor Gains
2M ago
COGT
Premium
The Fly
Cogent Biosciences reports Q4 net loss $102.5M vs. $67.9M last year
2M ago
COGT
Premium
The Fly
Cogent Biosciences sees cash runway into 2028
2M ago
COGT
Premium
Ratings
Cogent Biosciences: Breakthrough Bezuclastinib Data, Expanding SM Franchise, and Emerging Pipeline Support Raised $54 Buy Target
3M ago
COGT
Premium
The Fly
Cogent Biosciences announcse U.S. BTD for bezuclastinib
3M ago
COGT
Premium
Company Announcements
Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial
3M ago
COGT
Premium
The Fly
Cogent to initiate New Drug Application submission for bezuclastinib
3M ago
COGT
Premium
Ratings
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Multiple 2026 NDA Filings Underpin Reiterated Buy and $52 Target
3M ago
COGT
Premium
The Fly
Cogent Biosciences announces anticipated 2026 commercial, clinical milestones
3M ago
COGT
Premium
The Fly
Aligos Therapeutics initiated with a Buy at UBS
3M ago
IVA
KOD
Premium
Ratings
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Favorable FDA Outlook Underpin Upgraded $52 Buy Rating
3M ago
COGT
Premium
The Fly
Cogent Biosciences price target raised to $52 from $50 at H.C. Wainwright
3M ago
COGT
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
